Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -179M | -142M | -105M | -107M | -71M |
| EBITDA | -178M | -142M | -105M | -107M | -71M |
| Net Income | -162M | -129M | -97M | -105M | -71M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$11.43
+2.60% today
Window Change
-27.90%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Olema Pharmaceuticals, Inc. (OLMA) is a Healthcare stock with a market cap of $1.25B and listed on NASDAQ. The stock last traded around $11.43 and down 27.9% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +15.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +15.0%, free cash flow -40.4% with operating margin 0.0% and ROIC -37.0%. Stock Foundry combines OLMA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OLMA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OLMA Max Drawdown
-30.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for OLMA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$71.1M
+32.2% YoY
Free Cash Flow
-$52.3M
+36.6% YoY
Revenue Growth
+0.0%
EPS Growth
+15.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -179M | -142M | -105M | -107M | -71M |
| EBITDA | -178M | -142M | -105M | -107M | -71M |
| Net Income | -162M | -129M | -97M | -105M | -71M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 48M | 139M | 69M | 24M | 14M |
| Total Assets | 533M | 451M | 277M | 216M | 296M |
| Total Liabilities | 55M | 42M | 23M | 18M | 11M |
| Shareholder Equity | 479M | 409M | 254M | 198M | 285M |
| Total Debt | 1M | 1M | 2M | 3M | 3M |
| Net Debt | -47M | -138M | -66M | -21M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
51M
+38.2% YoY
Capital Expenditures
2M
-333.9% YoY
Free Cash Flow
52M
+36.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-42.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.